Get the Stockscreener App
1,052.57
0.20%
-1.7151
Overview
News
Price History
Option Chain
Financials
Why LLY Down?
Discussions
Forecast
Stock Split
Dividend History
Lilly Eli Co stock is traded at $1,052.57, with a volume of 1.56M.
It is down -0.20% in the last 24 hours and up +2.98% over the past month.
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$1,054.29
Open:
$1064.3
24h Volume:
1.56M
Relative Volume:
0.41
Market Cap:
$940.94B
Revenue:
$59.42B
Net Income/Loss:
$18.41B
P/E Ratio:
52.06
EPS:
20.2197
Net Cash Flow:
$6.44B
1W Performance:
+5.89%
1M Performance:
+2.98%
6M Performance:
+32.98%
1Y Performance:
+35.13%
1-Day Range:
$1,048.51
$1,064.30
1-Week Range:
$987.00
$1,068.25
52-Week Range:
$623.78
$1,111.99
Lilly Eli Co Stock (LLY) Company Profile
Name
Lilly Eli Co
Sector
Industry
Phone
(317) 276-2000
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Compare LLY with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LLY
Lilly Eli Co
|
1,051.31 | 943.61B | 59.42B | 18.41B | 6.44B | 20.22 |
|
JNJ
Johnson Johnson
|
210.32 | 504.27B | 92.15B | 25.12B | 20.46B | 10.36 |
|
ABBV
Abbvie Inc
|
225.13 | 395.31B | 59.64B | 2.36B | 19.68B | 1.3253 |
|
NVS
Novartis Ag Adr
|
135.49 | 259.09B | 54.45B | 14.42B | 17.15B | 7.333 |
|
MRK
Merck Co Inc
|
98.75 | 243.91B | 63.90B | 19.05B | 13.05B | 7.5596 |
Lilly Eli Co Stock (LLY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-13-25 | Initiated | Scotiabank | Sector Outperform |
| Nov-10-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-20-25 | Reiterated | BMO Capital Markets | Outperform |
| Oct-14-25 | Upgrade | Erste Group | Hold → Buy |
| Sep-17-25 | Downgrade | Berenberg | Buy → Hold |
| Aug-27-25 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-18-25 | Downgrade | Daiwa Securities | Outperform → Neutral |
| Aug-07-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Jun-05-25 | Downgrade | Erste Group | Buy → Hold |
| Apr-28-25 | Downgrade | HSBC Securities | Buy → Reduce |
| Apr-22-25 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-24 | Resumed | BofA Securities | Buy |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-17-24 | Initiated | Bernstein | Outperform |
| Sep-13-24 | Resumed | Citigroup | Buy |
| Aug-12-24 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-21-24 | Downgrade | DZ Bank | Buy → Hold |
| Feb-16-24 | Reiterated | Morgan Stanley | Overweight |
| Dec-21-23 | Downgrade | Daiwa Securities | Buy → Outperform |
| Nov-09-23 | Initiated | Deutsche Bank | Hold |
| Oct-20-23 | Resumed | UBS | Buy |
| Aug-09-23 | Upgrade | Jefferies | Hold → Buy |
| Jul-26-23 | Reiterated | Citigroup | Buy |
| Jul-14-23 | Initiated | HSBC Securities | Buy |
| May-24-23 | Reiterated | BofA Securities | Buy |
| May-24-23 | Reiterated | UBS | Buy |
| Mar-13-23 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-06-23 | Initiated | Jefferies | Hold |
| Feb-15-23 | Downgrade | Societe Generale | Hold → Sell |
| Nov-18-22 | Initiated | Credit Suisse | Outperform |
| Sep-22-22 | Upgrade | UBS | Neutral → Buy |
| May-23-22 | Initiated | SVB Leerink | Outperform |
| Apr-06-22 | Resumed | Morgan Stanley | Overweight |
| Mar-10-22 | Initiated | Daiwa Securities | Outperform |
| Jan-21-22 | Upgrade | DZ Bank | Hold → Buy |
| Jan-03-22 | Reiterated | Bernstein | Mkt Perform |
| Dec-17-21 | Initiated | Goldman | Neutral |
| Dec-16-21 | Reiterated | BMO Capital Markets | Outperform |
| Dec-16-21 | Reiterated | BofA Securities | Buy |
| Dec-09-21 | Resumed | Wells Fargo | Equal Weight |
| Nov-19-21 | Initiated | BMO Capital Markets | Outperform |
| Oct-11-21 | Upgrade | Berenberg | Hold → Buy |
| Sep-29-21 | Upgrade | Citigroup | Neutral → Buy |
| Aug-05-21 | Upgrade | DZ Bank | Hold → Buy |
| Jul-27-21 | Resumed | Truist | Buy |
| Jun-24-21 | Reiterated | Cantor Fitzgerald | Overweight |
| Jan-19-21 | Upgrade | Mizuho | Neutral → Buy |
| Dec-10-20 | Upgrade | Wolfe Research | Peer Perform → Outperform |
| Nov-10-20 | Resumed | Bernstein | Mkt Perform |
| Sep-29-20 | Initiated | Berenberg | Hold |
| Sep-03-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jun-16-20 | Upgrade | Guggenheim | Neutral → Buy |
| Apr-21-20 | Downgrade | UBS | Buy → Neutral |
| Apr-09-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Feb-06-20 | Initiated | Mizuho | Neutral |
| Dec-18-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-28-19 | Initiated | Goldman | Buy |
| Apr-24-19 | Upgrade | Edward Jones | Hold → Buy |
| Apr-11-19 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-12-19 | Initiated | JP Morgan | Overweight |
| Jan-23-19 | Initiated | UBS | Buy |
| Nov-26-18 | Downgrade | Citigroup | Buy → Neutral |
| Oct-31-18 | Upgrade | Credit Suisse | Underperform → Neutral |
| Oct-09-18 | Initiated | Guggenheim | Buy |
| Oct-01-18 | Reiterated | SunTrust | Buy |
| Sep-26-18 | Resumed | JP Morgan | Overweight |
View All
Lilly Eli Co Stock (LLY) Latest News
Judge Trims Lilly Suit Over Mass Produced Copycat Obesity Drugs - Bloomberg Law News
Eli Lilly’s Pediatric COVID-19 Study on Baricitinib Terminated: Key Insights for Investors - TipRanks
Eli Lilly Stock News Today (Dec. 17, 2025): LLY Holds Near Record Highs as Analysts Lift Targets and Obesity Pipeline Momentum Builds - ts2.tech
Billionaire With 30 Years of 30% CAGR Gains Dumped Nvidia, Palantir, and Eli Lilly - 24/7 Wall St.
Deutsche Bank Adjusts Price Target on Eli Lilly to $1,200 From $1,000, Maintains Buy Rating - marketscreener.com
TruWealth Advisors LLC Purchases 1,437 Shares of Eli Lilly and Company $LLY - MarketBeat
Eli Lilly’s $6 billion facility: ‘Merry Christmas and Happy New Year to the city of Huntsville’ - AL.com
Medi&Gene announces Catalyze agreement with Lilly - marketscreener.com
Eli Lilly and Company (NYSE:LLY) Upgraded by Daiwa America to Strong-Buy Rating - MarketBeat
The Ultimate High-Yield Drug Stock to Buy With $1,000 Right Now - The Motley Fool
MEDI&GENE Announces Catalyze Agreement with Lilly to Advance Next-Generation Obesity Therapeutics - WV News
Eli Lilly and Company $LLY Shares Purchased by Overbrook Management Corp - MarketBeat
Red Spruce Capital LLC Has $3.28 Million Stock Position in Eli Lilly and Company $LLY - MarketBeat
Nilsine Partners LLC Has $7.43 Million Holdings in Eli Lilly and Company $LLY - MarketBeat
St. Clair Advisors LLC Takes Position in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly and Company (NYSE:LLY) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
Healthy Returns: 2026 will be the year of obesity pills from Novo Nordisk, Eli Lilly - CNBC
Eli Lilly and Company Stock (LLY) Opinions on Retatrutide Trial Results - Quiver Quantitative
Is Eli Lilly a Buy Before 2026? - AOL.com
Eli Lilly's next-generation obesity drug secures first phase III win - MSN
Eli Lilly Stock (LLY) News, Forecasts and Outlook — Updated Dec. 16, 2025 - ts2.tech
Eli Lilly Shares Surge on Analyst Upgrade and Promising Drug Data - AD HOC NEWS
Lilly to participate in J.P. Morgan Healthcare Conference - marketscreener.com
Lilly leads with massive 15% dividend increase for 2026 - Rolling Out
Eli Lilly or Merck: Where Should Investors Put Their Money? - TradingView — Track All Markets
Here Are Tuesday’s Top Wall Street Analyst Research Calls: Allstate, Chubb Ltd., Eli Lilly, KLA Corp., Lockheed Martin, MongoDB, Roku, and More - AOL.com
Watts Gwilliam & Co. LLC Reduces Position in Eli Lilly and Company $LLY - MarketBeat
Lilly weight loss drug exceeds targets in Phase III trial - Longevity.Technology
The Alabama insider behind Eli Lilly’s $6 billion bet - Yellowhammer News
Rydar Equities Inc. Invests $1.25 Million in Eli Lilly and Company $LLY - MarketBeat
Why Is Novo Nordisk Stock Falling Tuesday?Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO) - Benzinga
LLY: Lawsuits Over Vision Loss Consolidated for Eli Lilly's Weig - GuruFocus
Eli Lilly and Company $LLY Shares Purchased by Corient Private Wealth LLC - MarketBeat
Where Will Eli Lilly Be in 10 Years? - Yahoo Finance
Analyst recommendations: Accenture, Albemarle, Eli Lilly, Gitlab, Okta… - marketscreener.com
Central Pacific Bank Trust Division Increases Stock Holdings in Eli Lilly and Company $LLY - MarketBeat
Eli Lilly’s New Study on LY4213663: A Potential Game-Changer for Rheumatoid Arthritis? - TipRanks
Two Engines Drive the Future, Market Continues Betting on Lilly - NAI500
Scotiabank remains bullish on Eli Lilly and Company (LLY) - MSN
Scotiabank Remains Bullish on Eli Lilly and Company (LLY) - Finviz
Eli Lilly (LLY): Revisiting Valuation After a Powerful Multi‑Month Share Price Rally - simplywall.st
Eli Lilly and Company (NYSE:LLY) Stock Price Up 3.4%Time to Buy? - MarketBeat
Top 20 by Trading Value | Accelerated Commercialization of FSD Boosts Tesla Over 3% to New Yearly High; Faster Approval Process for Weight-Loss Drugs Lifts Eli Lilly and Co Over 3%, Market Cap Breaks $1 Trillion Mark Again; NVIDIA Launches Next-Gen - 富途牛牛
Eli Lilly Stock (LLY) After Hours Today: What to Know Before the Market Opens Tuesday, Dec. 16, 2025 - ts2.tech
Eli Lilly & Co. stock outperforms competitors on strong trading day - MSN
2 Predictions for Eli Lilly in 2026 - AOL.com
Bank of America Says Market Isn’t Pricing in Eli Lilly’s (LLY) Weight-Loss Drug Dominance - TipRanks
Why Eli Lilly (LLY) Stock Is Trading Up Today - Finviz
Eli Lilly's Obesity Drug Dominance Still Underpriced By Market, Bank of America Says - Benzinga
Eli Lilly's GLP-1 Franchise to Drive 26% Revenue Growth in 2026, BofA Securities Says - marketscreener.com
Eli Lilly Stock (LLY) News Today: Retatrutide Breakthrough, Orforglipron FDA Timeline, and Analyst Forecasts on December 15, 2025 - ts2.tech
Lilly Eli Co Stock (LLY) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.14%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):